Compositions, systems, and methods for treating cancer using tumor treating fields and vegf inhibitors
AssigneeNovocure GmbH
InventorsTali Voloshin-Sela, Lilach AVIGDOR, Anat Klein-Goldberg
Life of this patent
Estimating the term…
Abstract
Compositions, systems, and methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field in combination with administration of at least one composition comprising at least one small molecule anti-angiogenic agent that specifically interacts with VEGF.
Claims20
A method of reducing viability of cancer cells, the method comprising the steps of:
- (1) administering at least one composition to the cancer cells, wherein the at least one composition comprises at least one small molecule anti-angiogenic agent that specifically interacts with either a vascular endothelial growth factor (VEGF) or a VEGF receptor (VEGFR) and selectively inhibits interaction between VEGF and VEGFR and/or inhibits VEGFR signal transduction at an IC50 of less than about 10 nmol/L;
- and
- (2) applying an alternating electric field to the cancer cells for a period of time.
A method of treating cancer in a subject, the method comprising the steps of:
- (1) administering at least one composition to the subject, wherein the at least one composition comprises at least one small molecule anti-angiogenic agent that specifically interacts with either a vascular endothelial growth factor (VEGF) or a VEGF receptor (VEGFR) and selectively inhibits interaction between VEGF and VEGFR and/or inhibits VEGFR signal transduction at an IC50 of less than about 10 nmol/L;
- and
- (2) applying an alternating electric field to a target region of the subject.
A method of reducing a volume of a tumor and/or preventing an increase of volume of the tumor, wherein the tumor is present in a body of a living subject and includes a plurality of cancer cells, the method comprising the steps of:
- (1) administering at least one composition to the subject, wherein the at least one composition comprises at least one small molecule anti-angiogenic agent that specifically interacts with either a vascular endothelial growth factor (VEGF) or a VEGF receptor (VEGFR) and selectively inhibits interaction between VEGF and VEGFR and/or inhibits VEGFR signal transduction at an IC50 of less than about 10 nmol/L;
- and
- (2) applying an alternating electric field to a target region of the subject.
Dependencies are inferred from the claim text.